Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Shipra Gandhi, Hongbin Chen, Yujie Zhao & Grace K Dy. (2015) First-line treatment of advanced ALK-positive non-small-cell lung cancer. Lung Cancer: Targets and Therapy 6, pages 71-82.
Read now
Read now
Brett Doble, Marcus Tan, Anthony Harris & Paula Lorgelly. (2015) Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist. Expert Review of Molecular Diagnostics 15:2, pages 235-254.
Read now
Read now
Francesca Farina, Alessandra Stasia & Carlo Gambacorti-Passerini. (2014) Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase. Blood and Lymphatic Cancer: Targets and Therapy 4, pages 69-79.
Read now
Read now
Articles from other publishers (15)
Ernest Nadal, Dolores Bautista, Luis Cabezón-Gutiérrez, Ana Laura Ortega, Héctor Torres, David Carcedo, Lucía Ruiz de Alda, J. Francisco Garcia, Paula Vieitez & Federico Rojo. (2021) Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario. BMC Cancer 21:1.
Crossref
Crossref
Zhenya Tang, Lu Wang, Guilin Tang & L. Jeffrey Medeiros. (2019) Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. International Journal of Molecular Sciences 20:16, pages 3939.
Crossref
Crossref
A.J. van der Wekken, R. Pelgrim, N. 't Hart, N. Werner, M.F. Mastik, L. Hendriks, E.H.F.M. van der Heijden, M. Looijen-Salamon, A.J. de Langen, J. Staal-van den Brekel, S. Riemersma, B.E. van den Borne, E.J.M. Speel, A-M.C. Dingemans, T.J.N. Hiltermann, A. van den Berg, W. Timens, E. Schuuring & H.J.M. Groen. (2017) Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research 23:15, pages 4251-4258.
Crossref
Crossref
Shingo Kamoshida. (2017) Prediction of response to cancer chemotherapy using immunohistochemical staining. Electrophoresis Letters 61:2, pages 124-127.
Crossref
Crossref
Guangming Tian, Xinliang Zhao, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Di Wu, Sen Han, Jieran Long, Yang Wang & Jian Fang. (2016)
Clinical characteristics associated with non-small-cell lung cancer harboring
ALK
rearrangements in Chinese patients
. Future Oncology 12:10, pages 1243-1249.
Crossref
Crossref
Hirokazu Taniguchi, Takaya Ikeda, Hiroshi Soda, Yuichi Fukuda, Takeshi Kitazaki, Yoichi Nakamura & Shigeru Kohno. (2016) Changes in Immunohistochemical Protein Levels in Anaplastic Lymphoma Kinase-positive Lung Adenocarcinoma Possibly due to Chemo-radiotherapy. Internal Medicine 55:13, pages 1775-1778.
Crossref
Crossref
Lorena San Miguel & Frank Hulstaert. (2015) The importance of test accuracy in economic evaluations of companion diagnostics. Journal of Comparative Effectiveness Research 4:6, pages 569-577.
Crossref
Crossref
Athina Markou, Ioanna Sourvinou, Ioanna Balkouranidou & Evi S. Lianidou. 2015. Biomarkers in Cancer. Biomarkers in Cancer
325
344
.
Charles Lim, Melissa Sergi & Natasha B Leighl. (2014) Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions. Lung Cancer Management 3:6, pages 477-489.
Crossref
Crossref
Darragh F. Halpenny, Gregory J. Riely, Sara Hayes, Helena Yu, Junting Zheng, Chaya S. Moskowitz & Michelle S. Ginsberg. (2014) Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?. Lung Cancer 86:2, pages 190-194.
Crossref
Crossref
Karen Zwaenepoel, Amber Van Dongen, Suzan Lambin, Christine Weyn & Patrick Pauwels. (2014)
Detection of ALK expression in non-small-cell lung cancer with
ALK
gene rearrangements - comparison of multiple immunohistochemical methods
. Histopathology 65:4, pages 539-548.
Crossref
Crossref
Julian C. Schink, Julia R. Trosman, Christine B. Weldon, Kalliopi P. Siziopikou, Gregory J. Tsongalis, Alfred W. Rademaker, Jyoti D. Patel, Al B. BensonIIIIII, Edith A. Perez & William J. Gradishar. (2014) Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. JNCI: Journal of the National Cancer Institute 106:10.
Crossref
Crossref
David ParkerMarc-Antoine Belaud-Rotureau. (2014)
Micro-cost Analysis of
ALK
Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
. Clinical Medicine Insights: Oncology 8, pages CMO.S19236.
Crossref
Crossref
Athina Markou, Ioanna Sourvinou, Ioanna Balkouranidou & Evi S. Lianidou. 2014. Biomarkers in Cancer. Biomarkers in Cancer
1
16
.
James E. Frampton. (2013) Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer. Drugs 73:18, pages 2031-2051.
Crossref
Crossref